Group 1 - Company completed a new round of financing exceeding 100 million yuan, led by Shunxi Fund and Yizhuang Guotou [2] - The company will focus on two core directions: R&D innovation and market expansion, enhancing its sustainable innovation capabilities [2] - The company aims to deepen cooperation with partners to explore broader commercial applications of gene sequencing technology [2] Group 2 - The company was established in 2015 and is a domestic NGS gene sequencing instrument enterprise using original research technology [2] - The company has successfully launched the S series and P series gene sequencers, with the S100 model receiving CE-IVDR certification and NMPA approval for clinical use [3] - The S200 sequencer is noted for its speed, data quality, and low operational costs, widely used in pathogen genome sequencing and infectious disease tracing [3]
顺禧基金、亦庄国投领投，基因测序企业赛纳生物完成超亿元新一轮融资
Sou Hu Cai Jing·2025-10-22 04:04